Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the